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Introduction
In the 1960s and 70s Wolf [1] was the ﬁ  rst to describe 
platelet derivatives of less than 0.1 μm as procoagulant 
vesicles. Later, having been given the name of ‘micro-
particles’ (MPs), these vesicles were described as 
membrane-derived nano-fragments (0.05 to 1 μm) that 
are active in coagulation and inﬂ   ammation. MPs are 
released in the extracellular environment through a 
membrane reorganization and blebbing process following 
cell activation or apoptosis. Th  ey constitute a storage 
pool of bioactive eﬀ  ectors with varied cellular origins and 
are able to act as intercellular messengers [2]. Th  ey are 
present in body ﬂ  uids where they reﬂ  ect normal tissue 
homeostasis, but undergo phenotypic and quantitative 
changes to play a pathophysiological role in several 
diseases, most of them associated with thrombotic 
disorders [3,4] (Figure 1).
MPs often convey tissue factor (TF) that may 
contribute to the dissemination of coagulopathy in sepsis 
[5,6] and cytokines up-regulating deleterious inﬂ  amma-
tory responses [7]. Circulating MPs can also provoke 
vascular dysfunction, and they reduce available nitric 
oxide (NO) and increase levels of reactive oxygen species, 
thereby promoting oxidative stress [8].
Th   is review will focus on the role of MPs during sepsis, 
with a special emphasis on  coagulation and inﬂ  ammation 
disturbances.
Microparticles are potential intercellular 
messengers during sepsis
Sepsis is a syndrome characterized by excessive cellular 
activation involving a systemic inﬂ  ammatory response to 
severe infection. Its most severe form may lead to septic 
shock. Th   e ongoing circulatory failure is characterized by 
vasoplegia-related arterial hypotension and may include 
vasopressor resistance, and myocardial and local blood 
ﬂ  ow impairments. Inﬂ  ammation plays a key role in the 
acute activation of the vascular wall and is associated 
with local thrombosis and changes in vasomotricity [9]. 
Th   us, the endothelium-derived TF initiates the coagula-
tion process and a proteolytic cascade [10]. Th  e endo-
thelial damage furthermore leads to the expression of 
adhesion molecules and other vasoactive factors involved 
in inﬂ  ammation and coagulation.
Biogenesis and general features of microparticles
MPs are produced following cellular activation or apop-
tosis. Th  e increase in intracellular calcium activates 
various cytosolic enzymes, including calpains, that cleave 
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© 2010 BioMed Central Ltdthe cytoskeleton and facilitate the role of procaspase-3 in 
apoptosis [11]. As a response to stimulus, the cyto-
skeleton is reorganized and the asymmetric distribution 
of the phospholipid membrane modiﬁ  ed with exposure 
of phosphatidylserine at the cell surface. Cellular blebbing 
then occurs, ultimately leading to the release of MPs. In 
addition to phosphatidylserine exposure, protein-lipid 
raft domains are formed and furnish the MP with its 
speciﬁ  cities and biological roles [12] (Figure 1).
Th  e cellular origin of MPs can be determined by 
assessment of the antigens that they expose at their 
surface. However, the complete protein content of MPs 
remains diﬃ     cult to establish. More than 300 proteins 
have been reported by proteomics, some of which are 
cytosolic and some membranous [13]. Th  e  MP  phenotype 
is, however, known to vary according to cellular origin 
and parental cell response to stimulus [7,14].
Microparticle survival and clearance
Although bearing phosphatidylserine, which is a signal 
for phagocytosis, MPs seem to survive longer than their 
parental apoptotic cell, probably because of their size, 
which does not allow optimal exposure of a cluster of 
senescence signals. Dasgupta and colleagues [15] recently 
described the major role of lactadherin in the removal of 
phosphatidylserine-expressing platelet MPs from human 
Figure 1. Structure of microparticles. Microparticles (MPs) are released from diff  erent cell types under physiological and pathological conditions. 
The plasma membrane is reorganised with active externalisation of phosphatidylserine (PhtdSer; a negatively charged phospholipid) and 
internalisation of phosphatidylcholine (insert). MPs bear intracytoplasmic and membrane-bound eff  ectors from the originating cells, such as tissue 
factor (TF) and endothelial protein C receptor (EPCR) (endothelial cells and monocytes), CD-14 (monocytes) or glycoprotein (GP)Ibα-IX-V, P-selectin or 
integrins (platelets).
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Page 2 of 8plasma. Lactadherin is a macrophage opsonin that 
mediates the clearance of apoptotic lymphocytes and 
knockout lactadherin (-/-) mice have increased levels of 
circulating platelet MPs and a hypercoagulable state; 
lactadherin supplementation restores the normal 
clearance of MPs. To date, there are no data on the eﬀ  ect 
of MP clearance on the haemostatic balance under 
physiological or pathological settings.
Microparticles as messengers in blood fl  ow
As mediators of cellular communication, MPs are actors 
and possible mediators in the interplay between throm-
bosis and inﬂ  ammation, a process previously described 
for vascular injury in inﬂ  ammatory diseases [5]. Th  ey  can 
transfer receptors, organelles, mRNA and other proteins 
to target cells [16] and also comprise a secretion pathway 
for several cytokines, such as mature IL-1β [17]. Th  e 
multiple properties of MPs and the variety of their 
possible cellular targets support them having a key role in 
cell reprogramming and tissue remodeling with physio-
logical or pathological consequences [4]. Th  us, MPs 
could play a major role in propagating proinﬂ  ammatory 
and procoagulant states in sepsis. In the vascular 
compartment, including the arterial wall, the particular 
settings of sepsis and the tuning abilities of MPs point to 
the endothelium as a pivotal target [18,19].
How to detect and measure microparticles?
Th  e International Society for Th  rombosis and Haemo-
stasis (ISTH) provides information on technical 
procedures and recommendations for the detection and 
measurement of MPs. Although no standardized proce-
dures for MP measurement are available yet, a consensus 
is forming on blood sampling and MP isolation by 
centrifugation steps that avoid exosome contamination of 
MP samples [20]. Several assays and phenotyping 
methods coexist, but these are not necessarily compar-
able, thus making the interpretation of results across 
studies diﬃ   cult. MPs can be analyzed through capture 
techniques (using immobilized annexin V - a high aﬃ   nity 
probe for phosphatidylserine - quantitative assessment, 
or insolubilized antibodies for phenotyping) combined 
with a functional prothrombinase assay. Flow cytometry 
is another method for the study of MPs. Th  is method 
allows quantiﬁ  cation and determination of cellular origin 
via the use of speciﬁ  c  ﬂ   uorescent antibodies and 
calibration beads. Th   e protein content of MPs can also be 
assayed and expressed in molecular mass units [21]. 
Caution should be taken in the interpretation of MP 
analyses, taking into account the pitfalls of each method 
and the purpose of the experiment or clinical 
investigation. Furthermore, control cohorts are of prime 
importance in clinical investigations of MP pattern 
variations.
Microparticles as a player in coagulation disorders 
of sepsis
In the defence against pathogens, haemostasis is as 
fundamentally important as innate immunity and 
complement-mediated cell lysis. Haemostasis is activated 
during sepsis and septic shock, leading to thrombin and 
ﬁ  brin generation with dual eﬀ  ects: limitation of pathogen 
diﬀ  usion and invasion; and ﬁ  brin deposition in vessels, 
resulting in thrombotic microangiopathy or disseminated 
intravascular coagulopathy. As detailed above, MPs are 
eﬃ   cient  eﬀ   ectors in the haemostatic response and 
pathogenic markers of thrombotic disorders (Figure 2).
Microparticles and thrombin generation
Th  rombin generation requires activation of coagulation 
factors, which is made possible after their assembly on a 
catalytic surface constituted of anionic phospholipids. 
Cell activation constitutes the ﬁ   rst step by furnishing 
exposed phosphatidylserine with a negative charge. Th  e 
required remodelling of plasma membrane, resulting in 
phosphatidylserine translocation to the outer leaﬂ  et of 
the plasma membrane, occurs in platelets, endothelial 
cells and monocytes at sites of vascular damage or injury. 
Calcium ion-mediated interactions between gamma-
carboxyl groups of vitamin-K-dependent factors and 
phosphatidylserine comprise the key step in this 
assembly, explaining the eﬃ     cacy of anti-vitamin K 
treatments in hypercoagulable states [22].
At the monocyte surface a possible encrypted pre  formed 
TF would be de-encrypted by plasma membrane remodel-
ling, thereby allowing the (auto-)activation of factor VII. 
Indeed, TF expression at the surface of monocyte-derived 
MPs has been demonstrated during in vitro endotoxin 
stimulation [23]. Although TF is the primary initiator of 
blood coagulation, whether there is a blood-borne TF 
(activity) is still debated, but there is growing evidence that 
this activity is directly tied to MPs [5,24]. TF-bearing MPs 
can interact with neutrophil granulocytes by ‘paracrine 
transfer’, as demonstrated in vitro [25-27]. Circulating MPs 
bearing active TF have been associated with a thrombotic 
status in human meningo  coccal sepsis [28] and a primate 
Ebola fever model [29], pointing to their possible role in 
the dissemination of a procoagulant potential.
Microparticles and amplifi  cation loops in thrombin 
generation
TF-driven coagulation is under the control of Tissue 
factor pathway inhibitor (TFPI), an inhibitory complex, 
with factor Xa and protein S as cofactors. Although this 
inhibits TF-induced thrombin generation, thrombin is 
still generated during the propagation phase via the Josso 
loop: platelet-exposed factor XI (of megakaryocytic 
origin) is activated by the GPIbα-thrombin complex 
present on the surface of activated platelets. Activated 
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turn, be responsible for increased thrombin generation 
[30-32]. In addition to blood-borne TF conveyed by MPs, 
polymorphonuclear (PMN)-derived MPs likely contri-
bute to an additional ampliﬁ  cation loop in the generation 
of thrombin mediated by MPs (Figure 2).
MPs could contribute to such ampliﬁ   cation loops in 
sepsis. Indeed, ex vivo activation of human neutrophils by 
endotoxin, platelet activating factor or phorbol myris  tate 
acetate can generate MPs bearing active integrin αMβ2 
(CD11b/CD18), which is able to activate GPIbα [33,34].
Microparticles in the control of thrombin generation, 
cytoprotection and tissue remodelling
Interestingly, several cellular models showed that αMβ2 
exposed at the MP surface can interact with other ligands, 
such as urokinase plasminogen activator, plas  mino  gen and 
metalloproteases MMP-2 and -5, suggesting a role in 
ﬁ  brinolysis and in local tissue remodelling [30,34,35]. MPs 
may also display antithrombotic activities, which would be 
overwhelmed by procoagulant activities when MPs are 
released under highly thrombotic conditions, as observed 
during sepsis or myocardial infarction. Indeed, in puriﬁ  ed 
monocyte suspensions, thrombomodulin anti  coagulant 
activity and TF coexist at the MP surface, but when 
released by lipopolysaccharide treatment, the TF activity is 
predominant on MPs [31]. Th   e presence of the 
anticoagulant endothelial protein C receptor (EPCR) at the 
surface of endothelial-derived MPs (mpEPCR) is another 
example of a cytoprotective element attached to MPs [32]; 
EPCR is involved in the activation of anticoagulant protein 
C by the thrombin-thrombomodulin complex. mpEPCR, 
Figure 2. Microparticles and blood coagulation. (A) The plasma membrane of endothelial cells and monocytes is reorganised, with 
externalisation of phosphatidylserine - a negatively charged phospholipid - and encrypted tissue factor (TF) expression, allowing factor VII 
(FVIIa) activation and thrombin (FIIa) generation at the cell surface. Blebbing occurs, with release of microparticles (MPs) bearing TF, resulting 
in an increased surface for procoagulant reactions. Platelet adhesion and aggregation also occur with the release of MPs; platelets and MPs 
bear GPIbα, a cofactor for factor XI activation by thrombin, leading to the propagation phase with high levels of thrombin generation and fi  brin 
formation. Endothelial TF-bearing MPs allow transfer of TF to PMNs, increasing TF dissemination and thrombotic microangiopathy or disseminated 
intravascular coagulopathy. (B) TF initiation of blood coagulation is quickly down-regulated by tissue factor pathway inhibitor (TFPI) on endothelial 
and monocytic cell surfaces, as on MPs. Endothelial protein C receptor (EPCR)-bound protein C is activated by the thrombin-thrombomodulin 
complex and activated protein C (APC) inhibits factor Va and factor VIIIa, limiting the propagation phase of thrombin generation. EPCR-bound 
APC also regulates NF-ΚB, with cytoprotective eff  ects on endothelial cells and monocytes. APC induces blebbing, with emission of EPCR-bearing 
MPs able to activate protein C, resulting in the dissemination of anticoagulant and antiapoptotic activities. LPS, lipopolysaccharide; PhtdSer, 
phosphatidylserine; PMN, polymorphonuclear.
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Page 4 of 8released in response to activated protein C (APC), may 
switch the procoagu  lant properties of endothelial MPs to 
anti  coagulant and anti-apoptotic properties. On the 
surface of MPs bearing mpEPCR, APC inactivates 
procoagulant cofactors factor Va and factor VIIIa, 
thereby down-regulating thrombin generation. Because a 
circulating soluble form of EPCR (sEPCR) has been 
described in sepsis, and its concentration possibly 
correlates with the severity of the illness, the respective 
contributions of mpEPCR and sEPCR is a matter of clinical 
relevance. sEPCR binds protein C and APC, thereby 
blunting their actions. Th  e  eﬃ   cacy of therapeutic activated 
protein C (rhAPC; drotrecogin alfa (activated)) may 
depend on the balance between circulating sEPCR and 
mpEPCR [32]. Recent investigations in human endothelial 
cells reported that free rhAPC and rhAPC bound to 
mpEPCR have similar eﬀ   ects. rhAPC cleaves protease 
activated receptor-1 and induces signiﬁ  cant changes in the 
activation/inhibition of genes with direct anti-apoptotic 
eﬀ  ects or indirect cell barrier protective eﬀ  ects, the latter 
requiring transactivation of KDR (vascular endothelial 
growth factor receptor 2/kinase insert domain receptor) 
via the phosphoinositide 3-kinase-Akt pathway and S1P1 
(sphingosine 1-phosphate receptor) [36].
In sepsis, procoagulant MPs of endothelial, platelet, 
erythroid, and leukocyte origins have been reported 
[28,37].
Microparticles as potential eff  ectors in the 
infl  ammatory response of sepsis
Circulating MPs have been reported to be present in 
various inﬂ  ammatory diseases, including sepsis [7]. MPs 
are a source of phospholipids, a substrate for phospho-
lipase A2, which facilitates platelet aggregation [38,39]; 
they may also provoke vascular inﬂ  ammation  during 
sepsis via lysophosphatidic acid and facilitate chemo-
tactic migration of platelets and/or leukocytes to the 
endothelium, thus playing the role of trigger in the 
production of monocyte cytokines (IL-1β, IL-8 and 
tumour necrosis factor-α) [8,40,41] (Figure 3).
Microparticles targeting the endothelial function
During sepsis, the endothelial function is altered and the 
endothelial surface becomes proadhesive, procoagulant 
and antiﬁ  brinolytic [42]. Th  e endothelium is one of the 
primary targets of circulating MPs, as demonstrated by 
Barry and colleagues [43] in vitro. Indeed, they showed 
that arachidonic acid exposed by platelet MPs promotes 
the up-regulation of cyclooxygenase-2 (COX-2) and 
inter  cellular adhesion molecules in endothelial cells. 
Platelet-derived MPs have been shown to modulate 
interactions between monocytes and endothelial cells. 
Released proinﬂ   ammatory endothelial cytokines may 
themselves also contribute to the production of MPs [44], 
thereby amplifying the inﬂ  ammatory response and the 
consecu  tive alteration of the vascular function [45]. 
Platelet activat  ing factor present in endothelial cells and 
leuko  cytes is also involved in the proinﬂ  ammatory eﬀ  ect 
of MPs [46].
Endothelial microparticles and infl  ammatory status
Circulating MPs of endothelial origin may thus vary with 
respect to quantity and phenotype according to the 
endothelial response and have been reported in inﬂ  am-
matory diseases and disorders [47]; the endothelial 
response to inﬂ   ammation stimuli may be immediate, 
delayed or reﬂ  ect a chronic endothelial activation. Th  ey 
were reported to participate in the regulation of arterial 
tone in several diseases in which oxidative stress is 
involved, such as human acute coronary syndromes [48] 
or preeclampsia [49] associated with altered NO 
bioavailability [50].
Sepsis induces a phenotypic change of the endothelium 
and the endothelial surface becomes proinﬂ  ammatory, 
expresses cell adhesion molecules (intercellular cell 
adhesion molecule 1, vascular cell adhesion molecule 1) 
[51] and becomes prothrombotic through the increased 
expression of membrane TF and the inhibition of 
thrombomodulin and EPCR synthesis. In parallel, 
endothelial cells become capable of recruiting and 
activating platelets [52].
Microparticles contribute to the spreading of infl  ammatory 
and prothrombotic vascular status
MPs may be considered as both the cause and the 
consequence of inﬂ  ammatory diseases through multiple 
ampliﬁ  cation and regulatory loops aﬀ  ecting vascular cell 
functions. In vitro incubation of leukocyte-derived MPs 
with endothelial cells allowed Mesri and Altieri [53] to 
demonstrate their role in the secretion of inﬂ  ammatory 
IL-6 and in the production of TF [54]. Furthermore, 
platelet MPs are able to deliver RANTES at the inﬂ  amed 
endothelium, thus promoting leukocyte recruitment and 
diapedesis [55]. MPs may aﬀ  ect the smooth muscle tissue 
through the activation of the transcription factor NF-κB 
and favour the expression of inducible NO-synthase and 
COX-2, resulting in an increase in NO and vasodilator 
prostanoids, leading to arterial hyporeactivity [45].
Th  e interactions between platelets, leukocytes and 
endothelium clearly contribute to the vascular 
dysfunction observed in sepsis and various MPs were 
reported to alter the arterial wall directly or indirectly 
[56,57].
Endothelial MPs may play a role in the spread of sepsis 
inﬂ  ammatory responses leading to multiple organ dys-
func  tion [18,58]. Th  ey may participate in the potential-
isation of the procoagulant state associated with sepsis by 
providing renewed lipid surfaces of human endothelial 
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Page 5 of 8cells for the generation of thrombin and by up-regulating 
monocyte TF expression, as demonstrated in vitro [59]. 
In sepsis, blockade of the human TF pathway by TFPI is 
very quickly overridden, clearing the way for a 
detrimental procoagulant state [28]. Indeed, in humans, a 
single endotoxin administration provokes a signiﬁ  cant 
increase in endothelial-cell- or monocyte-derived MPs 
displaying potentiated TF [60]. Th   is state is worsened by 
the exhaustion and/or faulty activation of the two other 
regulatory molecules, antithrombin and APC.
Several reports illustrate well the cascade of interwoven 
events that link cellular activation, TF up-regulation, the 
release of MPs presenting active TF and the triggering of 
disseminated intravascular coagulopathy and shock 
[28,29]. With regard to vascular tone, MPs could promote 
the signiﬁ  cant vasoplegia observed in septic shock [8]. 
Arachidonic acid transfer may up-regulate COX-2 
expression and the production of prostacyclin, which is 
implicated in vasodilation and the inhibition of platelet 
activation [32].
Microparticles and oxidative stress
During sepsis, generated MPs are involved in the modi  ﬁ  -
cation of the oxidative status; they form micro  aggregates 
with circulating neutrophil granulocytes and markedly 
increase oxidative activity [8]. Subunits of NADPH 
oxidase have been identiﬁ  ed in endothelial- and platelet-
derived MPs associated with increased produc  tion of 
reactive oxygen species [18,61] (Figure 3).
Conclusion
Th  e systemic inﬂ   ammatory response that is a charac-
teristic feature of sepsis is a major cause of cellular 
dysfunction that may lead to the exaggerated generation 
of MPs. Th   ese plasma membrane fragments are circulat-
ing markers of vascular inﬂ  ammatory diseases. Th  ey  also 
Figure 3. Microparticles and infl  ammation in sepsis. During sepsis, microparticles (MPs) are shed from a variety of activated or apoptotic cells. 
MPs may be considered as both the cause and the consequence of infl  ammation through multiple amplifi  cation and regulatory loops aff  ecting 
vascular cells and functions. Thus, MPs contribute to the spread of infl  ammatory and prothrombotic vascular status and they may aff  ect the smooth 
muscle tissue through adhesion molecules, activation of NF-κB and the expression of inducible nitric oxide synthase and cyclooxygenase-2, with 
an increase in nitric oxide and vasodilator prostanoids, leading to arterial hyporeactivity. MPs form microaggregates with circulating neutrophil 
granulocytes and platelets and are involved in the modifi  cation of the oxidative status, markedly increasing oxidative activity. Subunits of NADPH 
oxidase have been identifi  ed in MPs associated with increased production of reactive oxygen species. AA, arachidonic acid; COX = cyclooxygenase; 
ICAM, intercellular cell adhesion molecule; iNOS, inducible NO-synthase; LPS, lipopolysaccharide; NO, nitric oxide; PAF, platelet activating factor; R, 
Rantes; ROS, reactive oxygen species; TF, tissue factor; VCAM, vascular cell adhesion molecule.
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Page 6 of 8behave as pathogenic shuttles able to disseminate their 
deleterious proinﬂ  amatory and procoagulant potential in 
the systemic circulation and may be implicated in the 
multiple organ dysfunction characterizing sepsis and 
septic shock. To date, however, we have insuﬃ   cient 
evidence to determine whether MPs are major players or 
bystanders in the development of the sepsis syndrome.
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